SCHEMBL418901

SCHEMBL418901

CC(=O)N1CCN(c2ccccc2CN(C)C(=O)CCCSc2ccc(O)cc2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.40
SMN1; SMN2 Q16637 7/20 0.40
KMT2A Q03164 5/20 0.40
RAB9A P51151 5/20 0.40
NPC1 O15118 4/20 0.40
MEN1 O00255 4/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 4/20 0.39
GAA P10253 3/20 0.39
MAPK1 P28482 2/20 0.39
KDM4E B2RXH2 2/20 0.38
NPSR1 Q6W5P4 3/20 0.37
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
LMNA P02545 1/20 0.36
ATM Q13315 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL416317 0.90 NCF1 (0.37) ALDH1A1SMN1; SMN2KMT2ARAB9ANPC1
SCHEMBL417266 0.90 SMN1; SMN2 (0.49) ALDH1A1SMN1; SMN2KMT2ARAB9ANPC1
SCHEMBL417690 0.88 SMN1; SMN2 (0.39) ALDH1A1SMN1; SMN2KMT2ARAB9ANPC1
SCHEMBL413145 0.87 NPC1 (0.39) ALDH1A1SMN1; SMN2KMT2ARAB9ANPC1
SCHEMBL418211 0.87 KMT2A (0.44) ALDH1A1SMN1; SMN2KMT2ARAB9ANPC1
SCHEMBL415247 0.87 MEN1 (0.41) ALDH1A1KMT2AMEN1MAPTKDM4E
SCHEMBL418219 0.86 NPC1 (0.35) ALDH1A1SMN1; SMN2KMT2ARAB9ANPC1
SCHEMBL414601 0.86 ALDH1A1 (0.40) ALDH1A1MAPTKDM4ECYP1A2CYP2D6
SCHEMBL417731 0.86 KMT2A (0.45) ALDH1A1KMT2ARAB9ANPC1KDM4E
SCHEMBL412453 0.85 KDM4E (0.42) ALDH1A1SMN1; SMN2KMT2ARAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120022054-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS LABORATOIRE BIODIM (FR) 2012-01-26 US claimed
EP-2196453-A1 Novel substituted aryl derivatives, their process of preparation and their therapeutical uses as anti-HIV agents Cellvir (FR) 2010-06-16 EP claimed
US-20120022054-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS LABORATOIRE BIODIM (FR) 2012-01-26 US disclosed
EP-2376431-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS LABORATOIRE BIODIM (FR) 2011-10-19 EP disclosed
WO-2010066847-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS CELLVIR (FR) 2010-06-17 WO disclosed
EP-2196453-A1 Novel substituted aryl derivatives, their process of preparation and their therapeutical uses as anti-HIV agents Cellvir (FR) 2010-06-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022054-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS HAVCR2, MAVS, EIF2AK2 ALDH1A1 455/4885SMN1; SMN2 4050/4885KMT2A 2843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.